Page 344 - Glucose Monitoring Devices

References 351

[47] Hovorka R, Kumareswaran K, Harris J, Allen JM, Elleri D, Xing D, et al. Overnight
closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes:
crossover randomised controlled studies. BMJ British Medical Journal 2011:342.
[48] Russell SJ, El-Khatib FH, Nathan DM, Magyar KL, Jiang J, Damiano ER. Blood
glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas.
Diabetes Care 2012;35(11):2148e55.
[49] Van Bon AC, Jonker LD, Koebrugge R, Koops R, Hoekstra JB, DeVries JH. Feasibility
of a bihormonal closed-loop system to control postexercise and postprandial glucose
excursions. Journal of Diabetes Science and Technology 2012;6(5):1114e22.
[50] Renukuntla VS, Ramchandani N, Trast J, Cantwell M, Heptulla RA. Role of glucagon-
like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a
closed loop setting with ePID algorithm. Journal of Diabetes Science and Technology
2014;8(5):1011e7.
[51] Zisser H, Dassau E, Lee JJ, Harvey RA, Bevier W, Doyle III FJ. Clinical results of an
automated artificial pancreas using technosphere inhaled insulin to mimic first-phase
insulin secretion. Journal of Diabetes Science and Technology 2015;9(3):564e72.
[52] Atlas E, Nimri R, Miller S, Grunberg EA, Phillip M. MD-logic artificial pancreas sys-
tem: a pilot study in adults with type 1 diabetes. Diabetes Care 2010;33(5):1072e6.
[53] Pinsker JE, Lee JB, Dassau E, Seborg DE, Bradley PK, Gondhalekar R, et al. Random-
ized crossover comparison of personalized MPC and PID control algorithms for the
artificial pancreas. Diabetes Care 2016;39(7):1135e42.
[54] Breton M, Farret A, Bruttomesso D, Anderson S, Magni L, Patek S, et al. Fully
integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control
maintains near normoglycemia. Diabetes 2012;61(9):2230e7.
[55] Hovorka R, Allen JM, Elleri D, Chassin LJ, Harris J, Xing D, et al. Manual closed-loop
insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised
crossover trial. Lancet 2010;375(9716):743e51.
[56] Castle JR, Engle JM, El Youssef J, Massoud RG, Yuen KC, Kagan R, et al. Novel use
of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes.
Diabetes Care 2010;33(6):1282e7.
[57] El-Khatib FH, Russell SJ, Magyar KL, Sinha M, McKeon K, Nathan DM, et al. Auton-
omous and continuous adaptation of a bihormonal bionic pancreas in adults and ado-
lescents with type 1 diabetes. The Journal of Cinical Endocrinology and Metabolism
2014;99(5):1701e11.
[58] O’Grady MJ, Retterath AJ, Keenan DB, Kurtz N, Cantwell M, Spital G, et al. The use
of an automated, portable glucose control system for overnight glucose control in
adolescents and young adults with type 1 diabetes. Diabetes Care 2012;35(11):
2182e7.
[59] Ruiz JL, Sherr JL, Cengiz E, Carria L, Roy A, Voskanyan G, et al. Effect of insulin
feedback on closed-loop glucose control: a crossover study. Journal of Diabetes
Science and Technology 2012;6(5):1123e30.
[60] Murphy HR, Kumareswaran K, Elleri D, Allen JM, Caldwell K, Biagioni M, et al.
Safety and efficacy of 24-h closed-loop insulin delivery in well-controlled pregnant
women with type 1 diabetes A randomized crossover case series. Diabetes Care
2011;34(12):2527e9.
[61] Del Favero S, Boscari F, Messori M, Rabbone I, Bonfanti R, Sabbion A, et al. Random-
ized summer camp crossover trial in 5- to 9-year-old children: outpatient wearable
artificial pancreas is feasible and safe. Diabetes Care 2016;39(7):1180e5.